Michel Sadelain

Oncology · 2002–2023

A researcher in the Science corpus: 24 papers; trusts 11 researchers and is trusted by 17 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 260 citations into it; #91 of 1,698 by trust here, #90 by citations
• Immunology — 170 citations into it; #755 of 2,160 by trust here, #319 by citations
• Molecular Biology — 166 citations into it; #10,391 of 17,773 by trust here, #3,004 by citations
• Genetics — 114 citations into it

Whom Michel Sadelain trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. R. Brentjens
2. J. Kochenderfer
3. D. Porter
4. R. Morgan
5. I. Rivière

Who trusts Michel Sadelain overall

1. Jang-Hwan Cho
2. C. Dunbar
3. S. Rafiq
4. Jennifer N. Brudno
5. James J. Collins
6. J. Kochenderfer
7. K. High
8. Kole T. Roybal
9. Robert C. Sterner
10. Wilson W. Wong

Papers from Michel Sadelain's perspective

Ordered by how strongly the researchers Michel Sadelain trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
2. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
3. The basic principles of chimeric antigen receptor (CAR) design (Cancer Discovery)
4. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased anti-leukemic efficacy in vivo (Molecular Therapy)
5. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. (Advances in Immunology)
6. C-reactive protein: a critical update. (Journal of Clinical Investigation)
7. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. (Blood)
8. Progress in human tumour immunology and immunotherapy (Nature)
9. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia (Nature)
10. Cancer Statistics, 2001 (Ca)

Their papers

• Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling (2009) — 3,533 citations
• Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation (2009) — 299 citations
• Therapeutic T cell engineering (2017) — 769 citations
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (2014) — 2,346 citations
• Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells (2015) — 779 citations
• Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection (2017) — 1,655 citations
• Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells (2012) — 841 citations
• Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. (2012) — 651 citations
• Gene therapy comes of age (2018) — 1,212 citations
• Senolytic CAR T cells reverse senescence-associated pathologies (2020) — 956 citations
• Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer (2023) — 1,108 citations
• Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy (2021) — 901 citations
• CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade (2018) — 1,122 citations
• Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (2018) — 2,147 citations
• Chimeric Antigen Receptor Therapy (2018) — 1,841 citations
• Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) (2018) — 722 citations
• Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. (2016) — 929 citations
• PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses (2013) — 719 citations
• CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia (2013) — 1,977 citations
• The basic principles of chimeric antigen receptor (CAR) design (2013) — 1,379 citations